Drugs /

lorvotuzumab mertansine

Back to Drugs List

Overview

Generic Name(s):
lorvotuzumab mertansine
NCI Definition [1]:
An immunoconjugate of a humanized murine monoclonal antibody (huN-901) and DMI, a semi-synthetic derivative of the plant-derived ansa macrolide maytansine. The antibody moiety of BB-10901 selectively attaches to CD56 antigen, a neural cell adhesion molecule (NCAM)) expressed on the surface of cells of small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Thus, the DMI conjugate is targeted specifically to CD56-expressing tumor cells, where it inhibits tubulin polymerization and assembly, resulting in inhibition of mitosis and cell cycle arrest in the S phase. (NCI04)

Clinical Trials

View Clinical Trials for lorvotuzumab mertansine

Lorvotuzumab mertansine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating lorvotuzumab mertansine, 1 is phase 2 (1 open).

NCAM1 Expression and NCAM1 Overexpression are the most frequent biomarker inclusion criteria for lorvotuzumab mertansine clinical trials.

Malignant peripheral nerve sheath tumor, neuroblastoma, and pleuropulmonary blastoma are the most common diseases being investigated in lorvotuzumab mertansine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Lorvotuzumab Mertansine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating lorvotuzumab mertansine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
imgn901, lorvotuzumab mertansine, hun901-dm1, anti-human ncam-1 monoclonal antibody n901, bb-10901
Drug Target(s) [2]:
NCAM1
NCIT ID [1]:
C38714

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.